.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Chinese Patent Office
US Department of Justice
Teva
Medtronic
Chubb
Merck
Harvard Business School
Mallinckrodt
Baxter

Generated: July 22, 2017

DrugPatentWatch Database Preview

COPAXONE Drug Profile

« Back to Dashboard

What is the patent landscape for Copaxone, and what generic Copaxone alternatives are available?

Copaxone is a drug marketed by Teva Pharms Usa and is included in one NDA. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has forty-four patent family members in twenty-seven countries.

The generic ingredient in COPAXONE is glatiramer acetate. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the glatiramer acetate profile page.

Summary for Tradename: COPAXONE

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list50
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:COPAXONE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 1996DISCNNoNo► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014RXYesYes8,232,250► Subscribe ► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014RXYesYes9,155,776► Subscribe ► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 2014RXYesYes► Subscribe► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 2002APRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: COPAXONE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-002Feb 12, 20026,620,847► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 20148,367,605► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 19966,620,847► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622-001Dec 20, 19966,939,539► Subscribe
Teva Pharms Usa
COPAXONE
glatiramer acetate
INJECTABLE;SUBCUTANEOUS020622-003Jan 28, 20146,342,476► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: COPAXONE

Drugname Dosage Strength RLD Submissiondate
glatiramer acetateInjection40 mg/mL, 1 mL pre-filled syringeCopaxone1/29/2014
glatiramer acetateInjection40 mg/mL, 1 mL pre-filled syringeCopaxone2/26/2014

International Patent Family for Tradename: COPAXONE

Country Document Number Estimated Expiration
China105770855► Subscribe
Singapore178495► Subscribe
New Zealand598661► Subscribe
Spain2424692► Subscribe
European Patent Office2949335► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Accenture
Federal Trade Commission
AstraZeneca
Chinese Patent Office
McKinsey
Baxter
Julphar
Cantor Fitzgerald
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot